Exicure to Present at Upcoming TIDES USA Oligonucleotide & Peptide Therapeutics Conference
May 09 2022 - 7:00AM
Business Wire
Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and
immunotherapeutic drugs utilizing spherical nucleic acid (SNA™)
technology, today announced a poster presentation at TIDES USA
2022, May 9-12, 2022.
Poster presentation: “Development of Spherical Nucleic Acids
Targeting SCN9A For the Treatment of Neuropathic Pain” – Poster
Board Assignment Number: 54
Exicure will have the poster for viewing both in-person and
virtually during the conference. Virtual posters will go live at
the start of the conference and will be available to conference
attendees for 2 weeks.
Exicure will add the poster to its website after the
conference.
About Exicure
Exicure, Inc. is an early-stage biotechnology company developing
nucleic acid therapies targeting ribonucleic acid against validated
targets to neurological disorders and hair loss. The team includes
a diverse scientific group with expertise in nucleic acid
chemistry, drug development and neuroscience. Headquartered in
Chicago, Illinois, the Company conducts its discovery and
development efforts in-house with a dedicated 30,000 square foot
facility, including rapid and automated high throughput nucleic
acid synthesis and screening.
For further information, see www.exicuretx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220509005183/en/
Media: Karen Sharma MacDougall 781-235-3060
ksharma@macdougall.bio
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Apr 2023 to Apr 2024